MLT-103 is under clinical development by Meletios Therapeutics and currently in Phase I for Viral Respiratory Tract Infection. According to GlobalData, Phase I drugs for Viral Respiratory Tract Infection does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MLT-103 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MLT-103 overview
MLT-103 is under development for the treatment of respiratory infections caused by viruses. It is administered through oral route.
It was under development for the treatment of coronavirus disease 2019 (COVID-2019) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), dengue infections, middle east respiratory syndrome (MERS), influenza virus H1N1, Nipah virus infections and unspecified enveloped virus infections.
Meletios Therapeutics overview
Meletios Therapeutics is a biotechnology company intended to fulfil the medical need for antiviral molecules against current and emerging diseases. The company is headquartered in Paris, Ile-de-France, France.
For a complete picture of MLT-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
